

# Contents

## PART I

### 1 Leukemia

Sue Zupanec • Deborah Tomlinson

<b>1.1</b>	<b>Introduction</b>	2
<b>1.2</b>	<b>Acute Lymphoblastic Leukemia</b>	3
1.2.1	Epidemiology	3
1.2.2	Etiology	4
1.2.3	Molecular Genetics	6
1.2.4	Symptoms and Clinical Signs	7
1.2.5	Diagnostics	8
1.2.6	Staging and Classification	9
1.2.7	Treatment	12
1.2.8	Prognosis	16
1.2.9	Follow-Up	16
1.2.10	Future Perspectives	17
1.2.11	Relapsed ALL	17
<b>1.3</b>	<b>Acute Myeloid Leukemia</b>	19
1.3.1	Epidemiology	19
1.3.2	Etiology	19
1.3.3	Molecular Genetics	20
1.3.4	Symptoms and Clinical Signs	20
1.3.5	Diagnostics	21
1.3.6	Staging and Classification	21
1.3.7	Treatment	22
1.3.8	Prognosis	24
1.3.9	Follow-Up	24
1.3.10	Future Perspectives	24
<b>1.4</b>	<b>Chronic Myeloid Leukemia</b>	25
1.4.1	Epidemiology and Etiology	25
1.4.2	Molecular Genetics	25
1.4.3	Symptoms and Clinical Signs	25
1.4.4	Diagnostics	26
1.4.5	Treatment	26
1.4.6	Prognosis	26
1.4.7	Future Perspectives	26
<b>1.5</b>	<b>Juvenile Myelomonocytic Leukemia</b>	26
<b>1.6</b>	<b>Langerhans Cell Histiocytosis</b>	27
1.6.1	Epidemiology and Etiology	27
1.6.2	Diagnostics	28
1.6.3	Symptoms and Clinical Signs	28
1.6.4	Treatment	29
1.6.5	Prognosis	29
<b>References</b>		29

### 2 Lymphoma

Sue Zupanec

<b>2.1</b>	<b>Lymphoma</b>	33
<b>2.2</b>	<b>Hodgkin Lymphoma</b>	33
2.2.1	Epidemiology	34
2.2.2	Etiology	34
2.2.3	Molecular Genetics	34
2.2.4	Symptoms and Clinical Signs	34
2.2.5	Diagnostics	36
2.2.6	Staging and Classification	38
2.2.7	Treatment	39
2.2.8	Prognosis	42
2.2.9	Follow-Up	43
2.2.10	Relapsed/Refractory HL	43
2.2.11	Future Perspectives	44
<b>2.3</b>	<b>Non-Hodgkin Lymphomas</b>	44
2.3.1	Epidemiology	44
2.3.2	Etiology	45
2.3.3	Molecular Genetics	45
2.3.4	Symptoms and Clinical Signs	46
2.3.5	Diagnostics	48
2.3.6	Staging and Classification	50
2.3.7	Treatment	50
2.3.8	Prognosis	54
2.3.9	Follow-Up	54
2.3.10	Treatment of Relapsed/Refractory NHL	55
2.3.11	Future Perspectives	55
<b>References</b>		56

### 3 Solid Tumor

Eleanor Hendershot

<b>3.1</b>	<b>Ewing's Sarcoma Family of Tumors</b>	60
3.1.1	Epidemiology	60
3.1.2	Etiology	60
3.1.3	Molecular Genetics	60
3.1.4	Symptoms and Clinical Signs	61
3.1.5	Diagnosis	61
3.1.6	Staging and Classification	63
3.1.7	Treatment	63
3.1.8	Prognosis	64

3.1.9	Follow-Up	65	3.6.9	Follow-Up	100
3.1.10	Future Perspectives	65	3.6.10	Future Directions	100
<b>3.2</b>	<b>Osteosarcoma</b>	65	<b>3.7</b>	<b>Rhabdomyosarcoma</b>	100
3.2.1	Epidemiology	66	3.7.1	Epidemiology	100
3.2.2	Etiology	66	3.7.2	Etiology	101
3.2.3	Molecular Genetics	66	3.7.3	Molecular Genetics	101
3.2.4	Signs and Symptoms	67	3.7.4	Symptoms and Clinical Signs	101
3.2.5	Diagnostics	67	3.7.5	Diagnostics	101
3.2.6	Staging and Classification	68	3.7.6	Staging and Classification	103
3.2.7	Treatment	68	3.7.7	Treatment	103
3.2.8	Prognosis	71	3.7.8	Prognosis	106
3.2.9	Follow-Up	71	3.7.9	Follow-Up	106
3.2.10	Future Perspectives	71	3.7.10	Future Perspectives	106
<b>3.3</b>	<b>Liver Tumors</b>	72	<b>3.8</b>	<b>Non-Rhabdomyosarcomatous Soft-Tissue Sarcomas</b>	107
3.3.1	Epidemiology	72	3.8.1	Alveolar Soft-Part Sarcoma	108
3.3.2	Etiology	72	3.8.2	Desmoid Tumor (Aggressive Fibromatosis)	108
3.3.3	Molecular Genetics	72	3.8.3	Desmoplastic Small Round Cell Tumor	108
3.3.4	Symptoms and Clinical Signs	72	3.8.4	Infantile Fibrosarcoma	109
3.3.5	Diagnostics	73	3.8.5	Infantile Hemangiopericytoma	109
3.3.6	Staging and Classification	74	3.8.6	Infantile Myofibromatosis	109
3.3.7	Treatment	75	3.8.7	Leiomyosarcoma	109
3.3.8	Prognosis	76	3.8.8	Liposarcoma	109
3.3.9	Follow-Up	76	3.8.9	Malignant Peripheral Nerve Sheath Tumor	110
3.3.10	Future Perspectives	77	3.8.10	Synovial Sarcoma	110
<b>3.4</b>	<b>Neuroblastoma</b>	77	<b>3.9</b>	<b>Germ Cell Tumors</b>	110
3.4.1	Epidemiology	77	3.9.1	Epidemiology	111
3.4.2	Etiology	77	3.9.2	Etiology	111
3.4.3	Molecular Genetics	77	3.9.3	Molecular Genetics	112
3.4.4	Symptoms and Clinical Signs	79	3.9.4	Symptoms and Clinical Signs	112
3.4.5	Diagnostics	80	3.9.5	Diagnostics	112
3.4.6	Staging and Classification	81	3.9.6	Staging and Classification	113
3.4.7	Treatment	82	3.9.7	Treatment	113
3.4.8	Prognosis	85	3.9.8	Prognosis	115
3.4.9	Follow-Up	85	3.9.9	Follow-Up	115
3.4.10	Future Perspectives	86	3.9.10	Future Perspectives	116
<b>3.5</b>	<b>Renal Tumors</b>	86	<b>3.10</b>	<b>Rare Tumors</b>	116
3.5.1	Epidemiology	86	3.10.1	Adrenocortical Carcinoma	116
3.5.2	Etiology	87	3.10.2	Melanoma	117
3.5.3	Molecular Genetics	87	3.10.3	Nasopharyngeal Carcinoma	118
3.5.4	Symptoms and Clinical Signs	87	3.10.4	Pleuropulmonary Blastoma	118
3.5.5	Diagnostics	88	3.10.5	Thyroid Carcinoma	119
3.5.6	Staging and Classification	89	<b>References</b>		119
3.5.7	Treatment	89			
3.5.8	Prognosis	92			
3.5.9	Follow-Up	93			
3.5.10	Future Perspectives	93			
<b>3.6</b>	<b>Retinoblastoma</b>	93	<b>4</b>	<b>Central Nervous System Tumors</b>	
3.6.1	Epidemiology	93		Nancy E. Kline • Joan O'Hanlon-Curry	
3.6.2	Etiology	94	<b>4.1</b>	<b>Causes/Epidemiology</b>	129
3.6.3	Molecular Genetics	94	<b>4.2</b>	<b>Distribution/Classification</b>	129
3.6.4	Signs and Symptoms	94	<b>4.3</b>	<b>Staging</b>	130
3.6.5	Diagnostics	95	<b>4.4</b>	<b>Molecular Genetics of Brain Tumors</b>	130
3.6.6	Staging and Classification	96			
3.6.7	Treatment	96			
3.6.8	Prognosis	99			

4.5	<b>Diagnosis</b> . . . . .	130
4.6	<b>Specialist Referral</b> . . . . .	130
4.7	<b>Hydrocephalus</b> . . . . .	130
4.8	<b>Treatment</b> . . . . .	131
	4.8.1 Surgery . . . . .	131
	4.8.2 Radiotherapy . . . . .	131
	4.8.3 Chemotherapy . . . . .	132
4.9	<b>Prognosis</b> . . . . .	132
4.10	<b>Specific Tumors</b> . . . . .	132
	4.10.1 PNETs/Medulloblastomas . . . . .	132
	4.10.2 Astrocytomas/Glial Tumors . . . . .	133
	4.10.3 Malignant Gliomas . . . . .	134
	4.10.4 Other High-Grade Gliomas . . . . .	134
4.11	<b>Follow-Up</b> . . . . .	138
	4.11.1 The Late Effects and Rehabilitation of Survivors . . . . .	138
	4.11.2 Palliative Care . . . . .	139
	4.11.3 Future Perspectives/New Innovations . . . . .	139
	<b>References</b> . . . . .	140

## PART II

### 5 Anemias

Rosalind Bryant

5.1	<b>Anemia</b> . . . . .	142
5.2	<b>Iron-Deficiency Anemia</b> . . . . .	146
	5.2.1 Epidemiology . . . . .	146
	5.2.2 Etiology . . . . .	146
	5.2.3 Molecular Genetics . . . . .	146
	5.2.4 Symptoms/Clinical Signs . . . . .	146
	5.2.5 Diagnostic Testing . . . . .	147
	5.2.6 Treatment . . . . .	148
	5.2.7 Transfusion . . . . .	148
	5.2.8 Erythropoietin (Epoen) . . . . .	148
	5.2.9 Prognosis . . . . .	149
5.3	<b>Sickle Cell Disease</b> . . . . .	149
	5.3.1 Epidemiology . . . . .	149
	5.3.2 Etiology . . . . .	149
	5.3.3 Molecular Genetics . . . . .	149
	5.3.4 Symptoms/Clinical Signs . . . . .	149
	5.3.5 Diagnostic Testing . . . . .	150
	5.3.6 Complications of SCD . . . . .	151
	5.3.7 Prognosis . . . . .	158
	5.3.8 Future Perspectives . . . . .	158
5.4	<b>Thalassemia</b> . . . . .	158
	5.4.1 Alpha ( $\alpha$ )-Thalassemia . . . . .	158
	5.4.2 Beta Thalassemia (Cooley Anemia) . . . . .	159
	5.4.3 Diagnostic Testing . . . . .	160
	5.4.4 Treatment . . . . .	160
	5.4.5 Treatment of Hemosiderosis (Iron Overload) . . . . .	160
	5.4.6 Chelation Therapy . . . . .	161

	5.4.7 Clinical Advances (Hemosiderosis) . . . . .	161
	5.4.8 Prognosis . . . . .	161
	5.4.9 Follow-Up . . . . .	162
	5.4.10 Future Perspectives . . . . .	162
5.5.	<b>Hemolytic Anemia</b> . . . . .	162
	5.5.1 Hereditary Spherocytosis . . . . .	162
	5.5.2 Autoimmune Hemolytic Anemia . . . . .	164
	5.5.3 Glucose-6-Phosphate Dehydrogenase Deficiency . . . . .	165
5.6	<b>Bone Marrow Failure Syndromes</b> . . . . .	167
	5.6.1 Aplastic Anemia . . . . .	167
	<b>References</b> . . . . .	170

### 6 Neutropenia

Karyn Brundige

6.1	<b>Epidemiology</b> . . . . .	173
6.2	<b>Etiology</b> . . . . .	174
6.3	<b>Symptoms and Clinical Signs</b> . . . . .	175
6.4	<b>Diagnostic Testing</b> . . . . .	175
6.5	<b>Treatment</b> . . . . .	176
6.6	<b>Prognosis</b> . . . . .	177
6.7	<b>Follow-Up</b> . . . . .	178
	<b>References</b> . . . . .	178

### 7 Thrombocytopenia

Karyn Brundige

7.1	<b>Epidemiology</b> . . . . .	179
7.2	<b>Etiology</b> . . . . .	180
7.3	<b>Symptoms and Clinical Signs</b> . . . . .	180
7.4	<b>Diagnostic Testing</b> . . . . .	182
7.5	<b>Treatment</b> . . . . .	182
7.6	<b>Prognosis</b> . . . . .	184
7.7	<b>Follow-Up</b> . . . . .	184
7.8	<b>Future Perspectives</b> . . . . .	184
	<b>References</b> . . . . .	184

### 8 Bleeding Disorders

Joan O'Brien-Shea

8.1	<b>Hemophilia</b> . . . . .	187
	8.1.1 Epidemiology . . . . .	187
	8.1.2 Etiology . . . . .	187
	8.1.3 Genetics . . . . .	188
	8.1.4 Symptoms and Clinical Signs . . . . .	188
	8.1.5 Diagnostic Testing . . . . .	190
	8.1.6 Treatment . . . . .	191
	8.1.7 Prognosis . . . . .	194
	8.1.8 Follow-Up . . . . .	194

8.1.9	Future Perspectives . . . . .	194
<b>8.2</b>	<b>von Willebrand Disease</b> . . . . .	194
8.2.1	Epidemiology . . . . .	194
8.2.2	Etiology . . . . .	195
8.2.3	Genetics . . . . .	195
8.2.4	Symptoms and Clinical Signs . . . . .	195
8.2.5	Diagnostic Testing . . . . .	196
8.2.6	Treatment . . . . .	199
8.2.7	Prognosis . . . . .	200
8.2.8	Follow-Up . . . . .	200
<b>References</b>	. . . . .	201

### PART III

## 9 Chemotherapy

Christine Chordas • Kristen Graham

<b>9.1</b>	<b>Introduction</b> . . . . .	204
<b>9.2</b>	<b>Cancer Cell Characteristics</b> . . . . .	204
9.2.1	The Cell Cycle . . . . .	204
9.2.2	Cell Cycle Control . . . . .	205
<b>9.3</b>	<b>Chemotherapy</b> . . . . .	206
9.3.1	Principles . . . . .	206
9.3.2	Resistance . . . . .	206
9.3.3	The Principles of Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics . . . . .	206
9.3.4	Chemotherapy Techniques . . . . .	207
<b>9.4</b>	<b>Clinical Trials</b> . . . . .	207
9.4.1	Phase I Clinical Trials . . . . .	208
9.4.2	Phase II Clinical Trials . . . . .	208
9.4.3	Phase III Clinical Trials . . . . .	208
9.4.4	Phase IV Clinical Trials . . . . .	208
<b>9.5</b>	<b>Chemotherapy Agents</b> . . . . .	208
9.5.1	Antimetabolites . . . . .	211
9.5.2	Alkylating Agents . . . . .	216
9.5.3	Antitumor Antibiotics . . . . .	217
9.5.4	Anthracycline Antibiotics . . . . .	218
9.5.5	Plant Derivatives . . . . .	218
9.5.6	Antiangiogenic Agents . . . . .	219
9.5.7	Miscellaneous Agents . . . . .	220
<b>9.6</b>	<b>Chemotherapy Protectants</b> . . . . .	221
9.6.1	Allopurinol (Zyloprim) . . . . .	221
9.6.2	Amifostine (Ethyol) . . . . .	221
9.6.3	Dexrazoxane (Zincard) . . . . .	221
9.6.4	Leucovorin Calcium (LCV, Wellcovorin, Citovorin Factor, Folic Acid) . . . . .	221
9.6.5	Mesna (Mesnex) . . . . .	221
9.6.6	Palifermin . . . . .	222
<b>9.7</b>	<b>Administration of Chemotherapy Agents</b> . . . . .	222
9.7.1	Preparation . . . . .	222
9.7.2	Administration and Practice Considerations . . . . .	223

<b>9.8</b>	<b>Professional Guidelines to Minimize the Risk of Medication Errors</b> . . . . .	224
9.8.1	Prescribing Errors . . . . .	224
<b>9.9</b>	<b>Safe Practice Considerations</b> . . . . .	224
9.9.1	Mixing Chemotherapeutic Agents . . . . .	225
9.9.2	Transporting Cytotoxic Agents . . . . .	225
9.9.3	Safe Handling After Chemotherapy . . . . .	225
9.9.4	Disposal of Cytotoxic Materials . . . . .	225
9.9.5	Spill Management . . . . .	226
9.9.6	Procedures Following Accidental Exposure . . . . .	226
9.9.7	Storage . . . . .	226
9.9.8	Medical Management . . . . .	226
<b>9.10</b>	<b>Administration of Chemotherapy in the Home</b> . . . . .	226
<b>9.11</b>	<b>Immediate Complications of Chemotherapy Administration</b> . . . . .	226
9.11.1	Extravasation . . . . .	227
9.11.2	Acute Hypersensitivity Reactions (HSRs) to Chemotherapy . . . . .	230
9.11.3	Risk Factors for Hypersensitivity, Flare Reactions, or Anaphylaxis . . . . .	230
9.11.4	Recommended Steps to Prevent HSRs . . . . .	230
9.11.5	Emergency Management of HSR/Anaphylaxis . . . . .	230
<b>9.12</b>	<b>Summary</b> . . . . .	231
<b>References</b>	. . . . .	231

## 10 Radiotherapy

Irene Loch • Jane Khorrami

<b>10.1</b>	<b>Introduction</b> . . . . .	233
<b>10.2</b>	<b>Radiation</b> . . . . .	233
<b>10.3</b>	<b>Principles of Treatment</b> . . . . .	234
<b>10.4</b>	<b>Treatment Planning</b> . . . . .	234
10.4.1	CT Simulation . . . . .	234
10.4.2	Simulation . . . . .	234
<b>10.5</b>	<b>Treatment Methods</b> . . . . .	235
10.5.1	External Beam Radiotherapy (Teletherapy) . . . . .	235
10.5.2	Fractionation . . . . .	237
10.5.3	Total Body Irradiation (TBI) . . . . .	237
10.5.4	Brachytherapy . . . . .	237
10.5.5	Sealed Sources . . . . .	237
10.5.6	Unsealed Sources . . . . .	237
<b>10.6</b>	<b>Side Effects of Radiotherapy</b> . . . . .	238
10.6.1	Acute Effects . . . . .	238
<b>10.7</b>	<b>Special Considerations</b> . . . . .	240
10.7.1	Preparation of Children and Young People . . . . .	240
<b>10.8</b>	<b>Future Perspectives</b> . . . . .	240
10.8.1	Image-Guided Radiotherapy . . . . .	240

10.8.2	Intra-Operative Radiotherapy . . . . .	240
10.8.3	Proton Radiotherapy (PRT) . . . . .	240
<b>References</b>	. . . . .	241

## 11 Hematopoietic Stem Cell Transplantation

Robbie Norville • Deborah Tomlinson

<b>11.1</b>	<b>Principles of Treatment</b> . . . . .	243
<b>11.2</b>	<b>Stem Cell Collection (Harvest)</b> . . . . .	244
11.2.1	Bone Marrow Stem Cells . . . . .	244
11.2.2	Peripheral Blood Stem Cells . . . . .	246
11.2.3	Umbilical Cord Blood Stem Cells . . . . .	246
<b>11.3</b>	<b>Donor Stem Cell Typing/Tissue Typing</b> . . . . .	247
<b>11.4</b>	<b>Donor Stem Cell Sources</b> . . . . .	248
<b>11.5</b>	<b>Stem Cell Processing and Infusion</b> . . . . .	249
11.5.1	ABO Mismatch . . . . .	249
11.5.2	Graft vs. Leukemia . . . . .	251
<b>11.6</b>	<b>Description of Treatment</b> . . . . .	251
<b>11.7</b>	<b>Potential Side Effects</b> . . . . .	253
11.7.1	Early Side Effects . . . . .	253
11.7.2	Intermediate Side Effects . . . . .	257
11.7.3	Late Side Effects . . . . .	261
<b>11.8</b>	<b>Special Considerations</b> . . . . .	263
<b>11.9</b>	<b>Future Perspectives</b> . . . . .	264
<b>References</b>	. . . . .	265

## 12 Surgical Approaches to Childhood Cancer

Carol L. Rossetto

<b>12.1</b>	<b>Principles of Treatment</b> . . . . .	269
<b>12.2</b>	<b>Method of Delivery</b> . . . . .	270
12.2.1	Preoperative Evaluation . . . . .	270
12.2.2	Postoperative Nursing Care . . . . .	271
<b>12.3</b>	<b>Potential Side Effects</b> . . . . .	271
12.3.1	Complications of Medical Therapy Requiring Surgical Evaluation . . . . .	271
12.3.2	Complications Arising from Surgical Management of Solid Tumors . . . . .	272
<b>12.4</b>	<b>Special Considerations</b> . . . . .	273
12.4.1	Vascular Access Devices . . . . .	273
<b>12.5</b>	<b>Future Perspectives</b> . . . . .	274
12.5.1	New Surgical Techniques and Directions for Future Research . . . . .	274
<b>References</b>	. . . . .	275

## 13 Cell and Gene Therapy

Robbie Norville

<b>13.1</b>	<b>Introduction</b> . . . . .	277
<b>13.2</b>	<b>Principles of Treatment</b> . . . . .	278
13.2.1	Genetic Deficit Repair . . . . .	278
13.2.2	Viral-Mediated Gene Transfer . . . . .	278
13.2.3	Drug-Resistant Genes . . . . .	278
13.2.4	Angiogenetics Inhibitors . . . . .	279
13.2.5	Gene Marking . . . . .	279
13.2.6	Cell Therapy . . . . .	279
<b>13.3</b>	<b>Method of Delivery</b> . . . . .	279
13.3.1	Viral Vectors . . . . .	280
13.3.2	Plasmid Vectors . . . . .	280
<b>13.4</b>	<b>Potential Side Effects</b> . . . . .	280
<b>13.5</b>	<b>Special Considerations</b> . . . . .	281
<b>13.6</b>	<b>Future Perspectives</b> . . . . .	281
<b>References</b>	. . . . .	281

## 14 Biological and Targeted Therapies

Lindsay Gainer

<b>14.1</b>	<b>Introduction</b> . . . . .	283
<b>14.2</b>	<b>Principles of Treatment</b> . . . . .	284
<b>14.3</b>	<b>Description of Treatment</b> . . . . .	285
14.3.1	Cytokines . . . . .	285
14.3.2	Interferons . . . . .	285
14.3.3	Interleukins . . . . .	286
14.3.4	Colony-stimulating Factors . . . . .	286
14.3.5	Fusion Proteins . . . . .	286
14.3.6	Monoclonal Antibodies . . . . .	287
<b>14.4</b>	<b>Cancer Vaccines</b> . . . . .	288
<b>14.5</b>	<b>Other Immunomodulating Agents</b> . . . . .	288
14.5.1	Nonspecific Immunomodulating Agents . . . . .	288
14.5.2	Retinoids . . . . .	289
14.5.3	Thalidomide . . . . .	289
<b>14.6</b>	<b>Adoptive Immunotherapy</b> . . . . .	289
<b>14.7</b>	<b>Molecular Targeted Therapy</b> . . . . .	289
<b>14.8</b>	<b>Method of Delivery</b> . . . . .	290
<b>14.9</b>	<b>Potential Side Effects</b> . . . . .	291
<b>14.10</b>	<b>Future Perspectives</b> . . . . .	292
<b>References</b>	. . . . .	293

## 15 Complementary and Alternative Medicine

Janice Post-White • Elena Ladas

<b>15.1</b>	<b>Introduction</b> . . . . .	295
<b>15.2</b>	<b>CAM Modalities</b> . . . . .	296

15.2.1	Acupuncture	296
15.2.2	Biological Therapies	297
15.2.3	Mind–Body Therapies	299
15.2.4	Movement Therapies	300
15.2.5	Aromatherapy	301
15.2.6	Massage	302
15.2.7	Energy Therapies	303
<b>15.3</b>	<b>Future Perspectives</b>	303
<b>References</b>		304

## 16 Clinical Trials

Biljana Dzolganovski

<b>16.1</b>	<b>The Role of Clinical Trials</b>	307
16.1.1	The Need for Research	307
16.1.2	Phases of Clinical Trials	308
16.1.3	Study Types	308
16.1.4	Research Ethics: Principles, Policies, and Guidelines	308
16.1.5	Legal and Ethical Issues Regarding Participation of Children in Research	310
16.1.6	Research in Pediatrics	312
<b>16.2</b>	<b>Research Networks</b>	312
16.2.1	Cooperative Group Research	312
16.2.2	Importance of Participation in Clinical Trials	314
<b>16.3</b>	<b>Progress Made Through Clinical Trials</b>	315
16.3.1	Treatments and Therapy Delivery	315
16.3.2	Quality of Life Measures and Supportive Care	319
16.3.3	Complementary and Alternative Medicine	320
16.3.4	Late Effects	321
16.3.5	Palliative Care	321
<b>16.4</b>	<b>Perception of Clinical Trials</b>	322
<b>16.5</b>	<b>Future of Clinical Trials</b>	324
<b>16.6</b>	<b>The Role of the Clinical Research Associate</b>	324
16.6.1	Introduction	324
16.6.2	Clinical Research Associate	325
16.6.3	The Role of the CRA	326
16.6.4	The Role of the Clinical Research Nurse	328
<b>References</b>		329

## PART IV

### 17 Metabolic System

Deborah Tomlinson

<b>17.1</b>	<b>Cancer Cachexia</b>	337
17.1.1	Incidence	337
17.1.2	Etiology	338
17.1.3	Treatment	338

17.1.4	Prognosis	339
<b>17.2</b>	<b>Obesity</b>	339
17.2.1	Obesity in Survivors of Leukemia	339
<b>17.3</b>	<b>Inferior Outcomes and Obesity</b>	340
17.3.1	Incidence	340
17.3.2	Etiology	341
<b>17.4</b>	<b>Tumor Lysis Syndrome</b>	341
17.4.1	Incidence	341
17.4.2	Etiology	341
17.4.3	Treatment	343
17.4.4	Prognosis	347
<b>17.5</b>	<b>Hypercalcemia</b>	347
17.5.1	Incidence	347
17.5.2	Etiology	347
17.5.3	Treatment	347
17.5.4	Prognosis	348
<b>17.6</b>	<b>Impaired Glucose Tolerance</b>	348
17.6.1	Incidence	348
17.6.2	Etiology	348
17.6.3	Treatment	349
17.6.4	Prognosis	349
<b>References</b>		349

## 18 Gastrointestinal Tract

Anne Marie Maloney

<b>18.1</b>	<b>Mucositis</b>	354
18.1.1	Incidence	354
18.1.2	Etiology	354
18.1.3	Prevention	357
18.1.4	Treatment	357
18.1.5	Prognosis	358
<b>18.2</b>	<b>Dental Caries</b>	358
18.2.1	Incidence	358
18.2.2	Etiology	358
18.2.3	Prevention and Treatment	359
18.2.4	Prognosis	359
<b>18.3</b>	<b>Nausea and Vomiting</b>	359
18.3.1	Incidence	359
18.3.2	Etiology	359
18.3.3	Prevention	360
18.3.4	Treatment	360
18.3.5	Delayed Nausea and Vomiting	361
18.3.6	Anticipatory Nausea and Vomiting	361
18.3.7	Radiation-Induced Nausea and Vomiting	362
18.3.8	Other Causes of Nausea and Vomiting	363
18.3.9	Nonpharmacological Management	363
18.3.10	Prognosis	364
<b>18.4</b>	<b>Constipation</b>	364
18.4.1	Incidence	364
18.4.2	Etiology	364
18.4.3	Prevention	365
18.4.4	Treatment	365
18.4.5	Prognosis	366

<b>18.5</b>	<b>Diarrhea</b> . . . . .	366
18.5.1	Incidence . . . . .	366
18.5.2	Etiology . . . . .	366
18.5.3	Prevention . . . . .	368
18.5.4	Treatment . . . . .	368
18.5.5	Prognosis . . . . .	369
<b>18.6</b>	<b>Typhylitis</b> . . . . .	369
18.6.1	Incidence . . . . .	369
18.6.2	Etiology . . . . .	370
18.6.3	Prevention . . . . .	370
18.6.4	Treatment . . . . .	370
18.6.5	Prognosis . . . . .	371
<b>18.7</b>	<b>Perirectal Cellulitis</b> . . . . .	371
18.7.1	Incidence . . . . .	371
18.7.2	Etiology . . . . .	371
18.7.3	Prevention . . . . .	371
18.7.4	Treatment . . . . .	371
18.7.5	Prognosis . . . . .	372
<b>18.8</b>	<b>Acute Gastrointestinal Graft Vs. Host Disease</b> . . . . .	372
18.8.1	Incidence . . . . .	372
18.8.2	Prevention . . . . .	372
18.8.3	Treatment . . . . .	373
18.8.4	Prognosis . . . . .	374
<b>18.9</b>	<b>Chemical Hepatitis</b> . . . . .	374
18.9.1	Incidence . . . . .	374
18.9.2	Etiology . . . . .	374
18.9.3	Prevention . . . . .	374
18.9.4	Treatment . . . . .	374
18.9.5	Prognosis . . . . .	375
<b>18.10</b>	<b>Pancreatitis</b> . . . . .	375
18.10.1	Incidence . . . . .	375
18.10.2	Etiology . . . . .	375
18.10.3	Prevention . . . . .	375
18.10.4	Treatment . . . . .	375
18.10.5	Prognosis . . . . .	375
<b>References</b>		376

## 19 Bone Marrow Function

Sandra Doyle

<b>19.1</b>	<b>Introduction</b> . . . . .	380
<b>19.2</b>	<b>Anemia</b> . . . . .	380
19.2.1	Incidence and Etiology . . . . .	380
19.2.2	Treatment . . . . .	380
<b>19.3</b>	<b>Neutropenia</b> . . . . .	381
19.3.1	Incidence and Etiology . . . . .	381
19.3.2	Treatment . . . . .	382
<b>19.4</b>	<b>Thrombocytopenia</b> . . . . .	389
19.4.1	Incidence and Etiology . . . . .	389
19.4.2	Treatment . . . . .	389
<b>19.5</b>	<b>Transfusion Issues</b> . . . . .	390
19.5.1	Granulocyte Transfusions . . . . .	390
19.5.2	Transfusion-Associated Graft vs. Host Disease . . . . .	391

19.5.3	Cytomegalovirus and Transfusions . . . . .	392
19.5.4	Platelet Refractoriness . . . . .	392
<b>19.6</b>	<b>Disseminated Intravascular Coagulation</b> . . . . .	393
19.6.1	Etiology and Manifestation . . . . .	393
19.6.2	Treatment . . . . .	394
<b>19.7</b>	<b>Septic Shock</b> . . . . .	395
19.7.1	Etiology . . . . .	395
19.7.2	Treatment . . . . .	395
19.7.3	Prognosis . . . . .	396
<b>19.8</b>	<b>Immune Suppression</b> . . . . .	396
19.8.1	Polymorphonuclear Leukocytes . . . . .	396
19.8.2	Lymphocytes . . . . .	397
19.8.3	Spleen and Reticuloendothelial System . . . . .	398
19.8.4	Other Factors Contributing to Immunocompromised States . . . . .	398
<b>References</b>		398

## 20 Respiratory System

Margaret Parr

<b>20.1</b>	<b>Pneumocystis Pneumonia</b> . . . . .	401
20.1.1	Incidence . . . . .	401
20.1.2	Etiology . . . . .	402
20.1.3	Treatment . . . . .	402
20.1.4	Prognosis . . . . .	404
<b>20.2</b>	<b>Pneumonitis</b> . . . . .	404
20.2.1	Incidence . . . . .	404
20.2.2	Etiology . . . . .	404
20.2.3	Prevention . . . . .	405
20.2.4	Treatment . . . . .	405
20.2.5	Prognosis . . . . .	405
<b>20.3</b>	<b>Fibrosis</b> . . . . .	406
20.3.1	Incidence . . . . .	406
20.3.2	Etiology . . . . .	406
20.3.3	Prevention . . . . .	406
20.3.4	Treatment . . . . .	406
20.3.5	Prognosis . . . . .	406
<b>20.4</b>	<b>Compromised Airway</b> . . . . .	407
20.4.1	Incidence . . . . .	407
20.4.2	Etiology . . . . .	407
20.4.3	Prevention . . . . .	407
20.4.4	Treatment . . . . .	408
20.4.5	Prognosis . . . . .	408
<b>References</b>		408

## 21 Renal System

Fiona Reid

<b>21.1</b>	<b>Nephrectomy</b> . . . . .	412
21.1.1	Incidence . . . . .	412
21.1.2	Etiology . . . . .	412
21.1.3	Treatment . . . . .	412
21.1.4	Prognosis . . . . .	416

<b>21.2 Cytotoxic Drug Excretion</b> . . . . .	417
21.2.1 Pharmacokinetics/Dynamics . . . . .	417
21.2.2 Metabolism . . . . .	418
21.2.3 Excretion . . . . .	418
21.2.4 Drug Interactions . . . . .	420
21.2.5 Dose Modification . . . . .	420
21.2.6 Safe Handling of Cytotoxic Excreta . . . . .	424
<b>21.3 Nephrotoxicity</b> . . . . .	425
21.3.1 Incidence . . . . .	425
21.3.2 Etiology . . . . .	426
21.3.3 Prevention . . . . .	427
21.3.4 Treatment . . . . .	430
21.3.5 Prognosis . . . . .	432
<b>21.4 Hemorrhagic Cystitis</b> . . . . .	432
21.4.1 Incidence . . . . .	432
21.4.2 Etiology . . . . .	433
21.4.3 Prevention . . . . .	434
21.4.4 Treatment . . . . .	435
21.4.5 Prognosis . . . . .	437
<b>References</b> . . . . .	437

## 22 Cardiovascular System

Alison Hall

<b>22.1 Cardiac Toxicity/Cardiomyopathy</b> . . . . .	441
22.1.1 Incidence . . . . .	441
22.1.2 Etiology . . . . .	443
22.1.3 Treatment . . . . .	445
22.1.4 Prevention . . . . .	445
22.1.5 Prognosis . . . . .	447
<b>22.2 Venous Occlusive Disease</b> . . . . .	447
22.2.1 Hepatic Venous Occlusive Disease . . . . .	447
22.2.2 Pulmonary Venous Occlusive Disease . . . . .	449
<b>References</b> . . . . .	450

## 23 Central Nervous System

Jane Belmore • Deborah Tomlinson

<b>23.1 Spinal Cord Compression</b> . . . . .	453
23.1.1 Incidence . . . . .	453
23.1.2 Etiology . . . . .	453
23.1.3 Treatment . . . . .	454
23.1.4 Prognosis . . . . .	454
<b>23.2 Fatigue</b> . . . . .	454
23.2.1 Incidence . . . . .	455
23.2.2 Etiology . . . . .	455
23.2.3 Treatment . . . . .	456
23.2.4 Prognosis . . . . .	457
<b>23.3 Cognitive Deficits</b> . . . . .	458
23.3.1 Incidence . . . . .	458
23.3.2 Etiology . . . . .	458

23.3.3 Prevention and Treatment . . . . .	458
23.3.4 Prognosis . . . . .	459
<b>23.4 Diabetes Insipidus</b> . . . . .	459
23.4.1 Incidence . . . . .	459
23.4.2 Etiology . . . . .	460
23.4.3 Treatment . . . . .	460
23.4.4 Prognosis . . . . .	460
<b>References</b> . . . . .	460

## 24 Musculoskeletal System

Deborah Tomlinson • Sue Zupanec

<b>24.1 Bone Tumors</b> . . . . .	463
24.1.1 Limb Salvage Procedures . . . . .	463
24.1.2 Amputation . . . . .	464
24.1.3 Comparison of Limb Salvage and Amputation . . . . .	469
<b>24.2 Altered Bone Mineral Density and Increased Fracture Risk</b> . . . . .	470
24.2.1 Incidence . . . . .	470
24.2.2 Etiology . . . . .	471
24.2.3 Prevention and Treatment . . . . .	471
24.2.4 Prognosis . . . . .	472
<b>24.3 Osteonecrosis</b> . . . . .	472
24.3.1 Incidence . . . . .	473
24.3.2 Etiology . . . . .	474
24.3.3 Treatment . . . . .	474
24.3.4 Prognosis . . . . .	475
<b>References</b> . . . . .	475

## 25 Skin: Cutaneous Toxicities

Martina Nathan • Deborah Tomlinson

<b>25.1 Alopecia</b> . . . . .	477
25.1.1 Etiology . . . . .	477
25.1.3 Treatment . . . . .	478
25.1.4 Prognosis . . . . .	479
<b>25.2 Altered Skin Integrity Associated with Radiation Therapy</b> . . . . .	479
25.2.1 Incidence . . . . .	479
25.2.2 Etiology . . . . .	479
25.2.3 Prevention . . . . .	479
25.2.4 Treatment . . . . .	480
25.2.5 Prognosis . . . . .	481
<b>25.3 Radiation Sensitivity and Recall</b> . . . . .	481
25.3.1 Incidence . . . . .	481
25.3.2 Etiology . . . . .	481
25.3.3 Clinical Features . . . . .	481
25.3.4 Treatment . . . . .	481
25.3.5 Prognosis . . . . .	482
<b>25.4 Ultraviolet Recall Reaction/Photosensitivity</b> . . . . .	482



<b>25.5 Cutaneous Reactions Associated with High-Dose Cytosine Arabinoside</b> . . . . .	482
25.5.1 Incidence . . . . .	482
25.5.2 Etiology . . . . .	482
25.5.3 Prevention and Treatment . . . . .	482
<b>25.6 Nail Dystrophies</b> . . . . .	483
<b>25.7 Graft Vs. Host Disease</b> . . . . .	483
25.7.1 Incidence and Etiology . . . . .	483
25.7.2 Prevention . . . . .	485
25.7.3 Treatment . . . . .	486
25.7.4 Prognosis . . . . .	486
<b>References</b> . . . . .	486

## 26 Endocrine System

Julie Watson

<b>26.1 Introduction</b> . . . . .	489
<b>26.2 Hypothalamic–Pituitary Dysfunction</b> . . . . .	489
26.2.1 Incidence and Etiology . . . . .	489
<b>26.3 Growth Hormone Deficiency</b> . . . . .	491
26.3.1 Treatment . . . . .	492
26.3.2 Prognosis . . . . .	492
<b>26.4 Hypothalamic–Pituitary–Gonadal Axis</b> . . . . .	493
26.4.1 Gonadotrophin Deficiency . . . . .	493
26.4.2 Early or Precocious Puberty . . . . .	493
<b>26.5 Thyroid Disorders</b> . . . . .	494
26.5.1 Treatment . . . . .	494
<b>26.6 Hypothalamic–Pituitary–Adrenal Axis</b> . . . . .	495
26.6.1 Treatment . . . . .	495
<b>26.7 Other Pituitary Hormones</b> . . . . .	495
26.7.1 Fertility . . . . .	496
26.7.2 Treatment . . . . .	496
26.7.3 Prognosis . . . . .	497
<b>References</b> . . . . .	499

## 27 Ototoxicity

Colleen Nixon

<b>27.1 Introduction</b> . . . . .	501
<b>27.2 Prevention and Treatment</b> . . . . .	505
<b>27.3 Future Perspectives</b> . . . . .	507
<b>27.4 Prognosis</b> . . . . .	508
<b>References</b> . . . . .	508

## 28 Ocular Complications

Martina Nathan • Deborah Tomlinson

<b>28.1 Ocular Toxicity Associated with High-Dose Cytarabine Arabinoside</b> . . . . .	511
28.1.1 Incidence and Etiology . . . . .	511

28.1.2 Prevention . . . . .	512
28.1.3 Treatment . . . . .	512
28.1.4 Prognosis . . . . .	512
<b>28.2 Cataracts</b> . . . . .	513
28.2.1 Incidence . . . . .	513
28.2.2 Etiology . . . . .	513
28.2.3 Prevention . . . . .	513
28.2.4 Treatment . . . . .	513
28.2.5 Prognosis . . . . .	513
<b>References</b> . . . . .	513

## PART V

### 29 Nutrition and Hydration in Children with Cancer

Cheryl Rodgers • Sara Gonzalez

<b>29.1 Introduction</b> . . . . .	515
<b>29.2 Nutritional Assessment</b> . . . . .	516
29.2.1 Hydration Needs . . . . .	516
29.2.2 Nutrition Needs . . . . .	516
29.2.3 Nutritional History . . . . .	517
29.2.4 Physical Examination . . . . .	518
29.2.5 Anthropometric Measurements . . . . .	518
29.2.6 Laboratory Evaluation . . . . .	519
<b>29.3 Principles of Treatment for Dehydration and Malnutrition</b> . . . . .	519
29.3.1 Rehydration . . . . .	519
29.3.2 Oral Nutrition Replacement . . . . .	520
29.3.3 Enteral Nutrition Replacement . . . . .	520
29.3.4 Total Parenteral Nutrition/Hyperalimentation . . . . .	521
<b>29.4 Special Considerations</b> . . . . .	524
29.4.1 Common Hydration Complications . . . . .	524
29.4.2 Common Complications of Oral/Enteral Nutritional Supplementation . . . . .	524
29.4.3 Common Complications of Total Parenteral Nutrition/Hyperalimitation . . . . .	525
29.4.4 Common Complications of Enteral and Parenteral Nutritional Supplementation . . . . .	527
29.4.5 Specific Nutritional Concerns of Long-Term Survivors . . . . .	527
29.4.6 Specific Nutritional Concerns During Palliative Care . . . . .	527
<b>References</b> . . . . .	528

### 30 Pain in Children with Cancer

Cara Simon

<b>30.1 Introduction</b> . . . . .	529
<b>30.2 Causes of Pain in Childhood Cancer</b> . . . . .	529

<b>30.3</b>	<b>Assessment</b> . . . . .	530
<b>30.4</b>	<b>Cultural Issues</b> . . . . .	536
<b>30.5</b>	<b>Principles of Treatment</b> . . . . .	536
<b>30.6</b>	<b>Treatment</b> . . . . .	537
30.6.1	By the Ladder . . . . .	537
30.6.2	By the Route . . . . .	538
30.6.3	By the Clock . . . . .	538
30.6.4	Opioids . . . . .	538
30.6.5	Equianalgesia . . . . .	538
30.6.6	Procedure-Related Pain . . . . .	540
30.6.7	Patient-Controlled Analgesia (PCA) . . . . .	540
30.6.8	Adjuvant Medications . . . . .	542
30.6.9	Nonpharmacologic Treatment . . . . .	542
	<b>References</b> . . . . .	544

## 31 Blood Transfusion Therapy

Colleen Nixon

<b>31.1</b>	<b>Introduction</b> . . . . .	546
<b>31.2</b>	<b>Blood Screening Guidelines</b> . . . . .	546
<b>31.3</b>	<b>Blood Product Processing</b> . . . . .	546
31.3.1	Irradiation . . . . .	547
31.3.2	Washed Red Blood Cells . . . . .	547
<b>31.4</b>	<b>Transfusion Complications</b> . . . . .	547
31.4.1	Hemolytic Reactions . . . . .	547
31.4.2	Febrile Nonhemolytic Transfusion Reactions . . . . .	548
31.4.3	Allergic Reactions . . . . .	548
31.4.4	Transfusion Associated Graft vs. Host Disease . . . . .	549
31.4.5	Circulatory Overload . . . . .	549
31.4.6	Bacterial Contamination . . . . .	549
31.4.7	Transfusion-Acquired Infections . . . . .	550
31.4.8	Iron Overload from Chronic Transfusion . . . . .	551
<b>31.5</b>	<b>Red Blood Cell Transfusion</b> . . . . .	551
31.5.1	Packed Red Blood Cells . . . . .	551
31.5.2	Whole Blood . . . . .	552
31.5.3	Exchange Transfusion . . . . .	552
<b>31.6</b>	<b>Platelet Transfusion</b> . . . . .	552
31.6.1	Indications . . . . .	552
31.6.2	Procurement . . . . .	553
31.6.3	Dosing/Transfusion Guidelines . . . . .	553
31.6.4	Crossmatching . . . . .	553
31.6.5	Nursing Implications . . . . .	553
<b>31.7</b>	<b>Granulocyte Transfusion</b> . . . . .	553
31.7.1	Indications . . . . .	554
31.7.2	Dosing/Transfusion Guidelines . . . . .	554
31.7.3	Crossmatching . . . . .	554
31.7.4	Nursing Implications . . . . .	554
<b>31.8</b>	<b>Albumin (5 or 25% solution) and Plasma Protein Fraction (5% solution)</b> . . . . .	554
31.8.1	Indications . . . . .	554

31.8.2	Dosing/Transfusion Guidelines . . . . .	554
31.8.3	Crossmatching . . . . .	555
31.8.4	Nursing Implications . . . . .	555
<b>31.9</b>	<b>Fresh Frozen Plasma</b> . . . . .	555
31.9.1	Indications . . . . .	555
31.9.2	Dosing/Transfusion Guidelines . . . . .	555
31.9.3	Crossmatching . . . . .	555
31.9.4	Nursing Implications . . . . .	555
<b>31.10</b>	<b>Cryoprecipitate</b> . . . . .	555
31.10.1	Indications . . . . .	555
31.10.2	Dosing Guidelines . . . . .	556
31.10.3	Crossmatching . . . . .	556
31.10.4	Nursing Implications . . . . .	556
<b>31.11</b>	<b>Intravenous Immunoglobulin</b> . . . . .	556
31.11.1	Indications . . . . .	556
31.11.2	Dosing/Transfusion Guidelines . . . . .	556
31.11.3	Crossmatching . . . . .	556
31.11.4	Nursing Implications . . . . .	556
<b>31.12</b>	<b>Erythropoietin</b> . . . . .	556
<b>31.13</b>	<b>Indications</b> . . . . .	557
<b>31.14</b>	<b>Dosing Guidelines</b> . . . . .	557
<b>31.15</b>	<b>Nursing Implications</b> . . . . .	557
<b>31.16</b>	<b>Palliative Care Issues for Transfusion Therapy</b> . . . . .	557
31.16.1	Anemia and Thrombocytopenia . . . . .	557
	<b>References</b> . . . . .	557

## 32 Cytokines

Linda D'Andrea

<b>32.1</b>	<b>Principles of Treatment</b> . . . . .	559
<b>32.2</b>	<b>Future Perspectives</b> . . . . .	563
	<b>References</b> . . . . .	564

## 33 Care of the Dying Child and the Family

Angela M. Ethier

<b>33.1</b>	<b>Children's Understanding of Death</b> . . . . .	565
33.1.1	Infants (0–12 Months) and Toddlers (12–24 Months) . . . . .	565
33.1.2	Preschool Children (3–5 Years) . . . . .	566
33.1.3	School-Age Children (6–11 Years) . . . . .	567
33.1.4	Adolescents (12–19 Years) . . . . .	567
<b>33.2</b>	<b>Explaining Death to Children</b> . . . . .	567
<b>33.3</b>	<b>Pediatric Palliative Care</b> . . . . .	568
33.3.1	Principles . . . . .	568
33.3.2	Locations of Care . . . . .	568
<b>33.4</b>	<b>Grief</b> . . . . .	569
33.4.1	Principles . . . . .	569
33.4.2	Assessment of Child and Family . . . . .	569
33.4.3	Interventions . . . . .	571
<b>33.5</b>	<b>Cultural and Spiritual Care</b> . . . . .	571

33.5.1 Principles . . . . . 571

33.5.2 Assessment of Child and Family . . . . . 571

33.5.3 Interventions . . . . . 571

**33.6 Nearing Death . . . . . 573**

33.6.1 Physical Symptoms Near the End of Life 573

33.6.2 Death-Related Sensory Experiences . . . 574

**33.7 Care Following the Child's Death . . . . . 575**

33.7.1 Interventions Immediately Following the  
Child's Death . . . . . 575

33.7.2 Bereavement Interventions . . . . . 575

**33.8 Resources . . . . . 575**

33.8.1 Resources for Children . . . . . 575

33.8.2 Resources for Adults . . . . . 576

**References . . . . . 576**

---

**Subject Index . . . . . 579**